Milk Thistle

Phase 2Small molecule

UUniversity of Chicago

Milk Thistle is one of 20 small molecule programs targeting Pathological Gambling. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pathological GamblingActive, not recruiting

TrichotillomaniaActive, not recruiting

Pathological GamblingPhase 2

Active, not recruiting

TrichotillomaniaPhase 2

Active, not recruiting

Competition

Competitive Landscape

13 competitors in Trichotillomania

#DrugCompanyPhaseTrials

Ritalin

Novartis

Approved

1 2

Zoloft

VViatris Specialty LLC

Approved

1 3

Zyprexa

MMODAG GmbH

Approved

1 4

Acetadote

AArbor Pharmaceuticals, Inc.

Approved

—5

Marinol

Alnylam Pharmaceuticals

Phase 2

2 6

Ingrezza

Neurocrine Biosciences

Phase 2

1 7

Revia

Teva

Phase 2

1 8

Ozempic

Novo Nordisk

Phase 2

1 9

Cysteine Hydrochloride

Novartis

Phase 2

1 10

N-Acetyl Cyteien

SStanford University

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 2Recruiting

Pediatric NAFLD

NCT06477146

Clinical

Trials by Indication[1]

Pediatric NAFLD1 trial

Milk Thistle Clinical Trial in Pediatric NAFLD

Recruiting·UUniversity Hospitals Cleveland Medical Center·Phase 2·NCT06477146·20 enrolled

Trichotillomania1 trial

Milk Thistle in Trichotillomania in Children and Adults

Completed·UUniversity of Chicago·Phase 2·NCT02473913·22 enrolled

Pathological Gambling1 trial

Silymarin Treatment of Pathological Gambling: A Double-Blind, Placebo-Controlled Study

Completed·UUniversity of Chicago·Phase 2·NCT02337634·55 enrolled

Unspecified1 trial

Milk Thistle in Body Dysmorphic Disorder

Withdrawn·UUniversity of Chicago·Phase 2·NCT02843451

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Milk Thistle. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Milk Thistle compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Milk Thistle. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Chicago company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Chicago

Milk Thistle

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Pediatric NAFLD1 trial

Trichotillomania1 trial

Pathological Gambling1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News